Filter Results:
- Full text PDF available (16)
Publication Year
1955
2016
- This year (0)
- Last 5 years (10)
- Last 10 years (23)
Publication Type
Co-author
Journals and Conferences
Learn More
- Jiang Shou, Suleiman Alfred Massarweh, +4 authors Rachel Schiff
- Journal of the National Cancer Institute
- 2004
BACKGROUND
Patients receiving adjuvant tamoxifen whose tumors express high levels of both HER2/neu (HER2) and the estrogen receptor (ER) coactivator AIB1 often develop tamoxifen resistance. We used a… (More)
- Suleiman Alfred Massarweh, Caroline K Osborne, +6 authors Rachel Schiff
- Cancer research
- 2008
Not all breast cancers respond to tamoxifen, and many develop resistance despite initial benefit. We used an in vivo model of estrogen receptor (ER)-positive breast cancer (MCF-7 xenografts) to… (More)
- Grazia Arpino, Heidi Weiss, +4 authors Richard M. Elledge
- Journal of the National Cancer Institute
- 2005
BACKGROUND
Clinical data indicate that estrogen receptor-positive/progesterone receptor-negative (ER+/PR-) breast cancers are less sensitive to tamoxifen than are ER+/PR+ tumors. It has also been… (More)
- Y. P. Liang, Tuya Shilagard, +6 authors Stanley M Lemon
- Gastroenterology
- 2009
BACKGROUND & AIMS
Although hepatitis C virus (HCV) is a common cause of cirrhosis and liver cancer, efforts to understand the pathogenesis of HCV infection have been limited by the low abundance of… (More)
- Ann M. Leen, Anne Sanlaville Christin, +6 authors Catherine M. Bollard
- Journal of virology
- 2008
Adenoviral infections in the immunocompromised host are associated with significant morbidity and mortality. Although the adoptive transfer of adenovirus-specific T cells may prevent and treat such… (More)
- Y J Tham, Krystal Sexton, Heidi Weiss, Richard Elledge, Lois C. Friedman, Rita K Kramer
- American journal of clinical oncology
- 2007
OBJECTIVE
Adjuvant chemotherapy in premenopausal women with breast cancer may induce amenorrhea, which can affect fertility, choice of hormonal therapy, and increase the risk of late toxicity. The… (More)
- Ann M. Leen, Gregory Myers, +12 authors Catherine M. Bollard
- Nature Medicine
- 2006
Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are… (More)
- Chandrika J. Piyathilake, Andra R. Frost, +4 authors William E. Grizzle
- Clinical cancer research : an official journal of…
- 2002
PURPOSE
This study was conducted to evaluate the clinical significance of the localization of epidermal growth factor receptor (EGF-r), transforming growth factor (TGF)-alpha, and erbB-2 in the… (More)
- Catherine M. Bollard, Stephen Gottschalk, +12 authors Helen E Heslop
- Blood
- 2007
Epstein-Barr virus (EBV)-associated tumors developing in immunocompetent individuals present a challenge to immunotherapy, since they lack expression of immunodominant viral antigens. However, the… (More)
- Hong Wang, Craig Horbinski, +6 authors Chi Wang
- Nucleic acids research
- 2016
The advanced medium-throughput NanoString nCounter technology has been increasingly used for mRNA or miRNA differential expression (DE) studies due to its advantages including direct measurement of… (More)